Belvarafenib for BRAF-altered brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have a brain tumor (either one that started in the brain or spread from another cancer) with a specific BRAF gene change (mutation or fusion).
- Your tumor must have grown or come back after standard treatments, or no standard treatments are available.
- You must be able to take care of yourself (ECOG score 0-2) and have a life expectancy of at least 3 months.
- You must have adequate kidney, liver, and blood cell counts as shown by lab tests.
- You must agree to use effective birth control during the study and for 3 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
This trial tests a targeted drug, binimetinib, for people with low-grade glioma (a type of brain tumor) or pancreatic cancer that has a specific genetic change called a BRAF fusion. The drug aims to block signals that help these tumors grow.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Hear when a new Metastatic Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.